Lenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes

Lenalidomide is a novel thalidomide analogue with enhanced immunomodulatory and antiangiogenic action lacking most of the typical thalidomide-associated adverse events. In myelodysplastic syndromes (MDS), it has been used primarily in the IPSS low- and intermediate-1 risk setting. Several trials hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Giagounidis, Aristoteles A N, Germing, Ulrich, Haase, Sabine, Aul, Carlo
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2007
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374932/
https://www.ncbi.nlm.nih.gov/pubmed/18472976

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374932/
https://www.ncbi.nlm.nih.gov/pubmed/18472976

Ejemplares similares